Dabigatran Recalled Over Potential Carcinogen Ascend Laboratories LLC is recalling 10 lots of the oral anticoagulant dabigatran etexilate capsules (75 mg and 150 mg) because of unacceptable levels of a potential carcinogen.
Treat to LDL Target or High-Intensity Statin for All With Clinical CAD: LODESTAR How secondary prevention statins are given to push LDL cholesterol levels lower, whether in a high-intensity statin regimen or by dosage titration to meet LDL targets, may make little difference to clinical outcomes, suggests a randomized trial.
Sports-Related Sudden Cardiac Arrest 'Extremely' Rare in Women Sports-related sudden cardiac arrest (Sr-SCA) appears to be extremely rare in women compared with men, despite similar characteristics and circumstances of occurrence, data from three European population-based registries suggest.
Oral PCSK9 Inhibitor Shows Encouraging LDL Lowering A new oral formulation of a PCSK9-inhibitor, cholesterol-lowering drug in development by Merck has shown encouraging results in a phase 2 study. The study was presented by Christie Ballantyne, MD, Baylor College of Medicine, Houston, Texas at the recent American College of Cardiology (ACC) Scientific Session/World Congress of Cardiology (WCC) 2023.
Cardiovascular Risk Factors Rife in Argentine Cardiologists Despite cardiologists' knowledge about cardiovascular disease and risk factors, they have a high prevalence of these risk factors. This observation suggests poor working conditions for cardiologists of both sexes and a high prevalence of workplace gender violence for female cardiologists, according to a study conducted by the Argentine Society of Cardiology (SAC).
New Tool Better Estimates Cardiovascular Risk in People With Lupus A tool that incorporates lupus-related variables with traditional risk factors provides a much more accurate assessment of cardiovascular (CV) risk in patients with systemic lupus erythematosus (SLE), according to data presented at the annual meeting of the Canadian Rheumatology Association.
Dapagliflozin Gets Expanded Heart Failure Indication in Europe The European Commission (EC) has expanded the indication for dapagliflozin (Forxiga) to include heart failure (HF) across the full spectrum of left ventricular ejection fraction — including HF with mildly reduced and preserved ejection fraction, AstraZeneca has announced.
Cath Ablation for AF No Less Safe, Effective in Cancer Patients Catheter ablation for atrial fibrillation (AF) is effective and safe in patients with a history of cancer and those receiving cardiotoxic therapies. The ablation success rate in patients with cancer was similar to that observed in patients without cancer.
It’s not just what we eat, but why we eat that’s important for heart health The study found that emotional eating was associated with cardiovascular problems, and that stress contributed to this relationship.
Very Hot, Very Cold Days Tied to Higher CVD Mortality Extremely hot and extremely cold temperatures were associated with a greater risk of cardiovascular mortality in an analysis of data from countries around the world.
New ESH Hypertension Guidelines Aim for Simplified Message The European Society of Hypertension (ESH) has released updated and expanded guidelines for the management of hypertension.
The international activities of the Cardioprogress Foundation are expanding The Cardioprogress Foundation expands its international activities. A register of 7 thousand experts and an opinion of leaders from 46 countries of the world has been created.
Prof. Aronow's career path Dear colleagues! The Cardioprogress Foundation presents the excerpts from the memoirs of the International Journal of Heart and Vascular Diseases editorial board member Wilbert S. Aronov, a cardiologist, professor of medicine, member of the FACC, FAHA, FACP, FCCP, FASPC, AGSF, FGSA. Dr. Wilbert Solomon Aronow was born in New York City on October 30, 1931. His parents were Russian Jewish immigrants. His grandparents were rabbis in Russia. Doctor Aronov dedicated his professional career to medicine.
World Heart Day 2022 in Iloilo Iloilo province made history for hosting this year’s World Heart Day. It was chosen by the World Health Organization (WHO) as pilot area for the celebration. As highlight of the event, the whole façade of the Iloilo provincial capitol was illuminated on Thursday night, Sept. 29. The ceremonial event was led by Gov. Arthur Defensor Jr.; Department of Health (DOH) undersecretaries Dr. Kenneth Ronquillo and Atty. Charade Grande; DOH Western Visayas regional director, Dr. Adriano Zubaan; and representatives from WHO, Resolve to Save Lives, and World Heart Federation.
Climate change and health inequity a deadly mix for the most vulnerable: World Heart Federation Geneva, 29 September 2022 - On World Heart Day, the World Heart Federation (WHF) is calling for urgent action on climate change and health inequity, with millions more lives now at risk from cardiovascular disease, which is still the world’s biggest killer.
New ESC Guidelines for Cutting CV Risk in Noncardiac Surgery The European Society of Cardiology (ESC) guidelines on cardiovascular assessment and management of patients undergoing noncardiac surgery have seen extensive revision since the 2014 version. They still have the same aim — to prevent surgery-related bleeding complications, perioperative myocardial infarction/injury (PMI), stent thrombosis, acute heart failure, arrhythmias, pulmonary embolism, ischemic stroke, and cardiovascular (CV) death.
U.S. declares monkeypox public health emergency Following growing pressure to ramp up response efforts against monkeypox, the U.S. declared a public health emergency. There are around 6,600 infections nationwide, reaching all but two states. The White House plans to roll out several million doses of monkeypox vaccines and are targeting at-risk communities.
FDA Okays IN.PACT 018 Drug-Coated Balloon for PAD The US Food and Drug Administration has approved the IN.PACT 018 drug-coated balloon (DCB) for the treatment of peripheral arterial disease, Medtronic announced today.